

**PATENT/Docket No. PC11050A**  
Appl. No. 09/989,933  
Filing Date: November 21, 2001

**Amendments to the Specification:**

Please replace lines 16-20 on page 13 with the following amended paragraph:

The vaccine compositions of the present invention can also include additional active ingredient such as other vaccine compositions against BVDV, e.g., those described in ~~depending~~  
~~Application Serial No. 08/107,908, U.S. Patent No. 6,168,942, U.S. Patent No. 6,410,032, U.S. Patent~~  
~~No. 6,410,299, WO 9512682, WO 9955366, U.S. Patent No. 6,060,457, U.S. Patent No. 6,015,795, U.S.~~  
Patent No. 6,001,613, and U.S. Patent No. 5,593,873, all of which are incorporated by reference in their entirety.

Please replace lines 6-13 on page 15 with the following amended paragraph:

The DNA sequence of bovine polyubiquitin has been described by Meyers, G., et al. (*Virology*:180,602-616, 1991) and is present in GenBank (BOVPOUBA, Accession# M62429 M37794). Cloning and introduction of a monomeric ubiquitin into vector pvvNADLdINS2 involved two rounds of PCR amplification and synthesis of three PCR fragments. Plasmid pvvNADLdINS2 is a derivative of pvvNADL (an infectious clone of BVDV described in ~~U.S. Patent Application Serial No. 08/107,908, U.S. Patent No. 6,168,942, U.S. Patent No. 6,410,032, and U.S. Patent No. 6,410,299~~) in which the coding region of NS2 is deleted. In the first round, PCR fragments 1 and 2 were generated which then served as templates for the second round of PCR amplification resulting in PCR fragment 3 (Figure 1A).

BEST AVAILABLE COPY

BEST AVAILABLE COPY

FORM AMEND  
Rev. 5/27/03